Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Which pain block works best after C-Section? new trial aims to find out

NCT ID NCT04711096

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial compares two ways to manage pain after a cesarean section done under general anesthesia: an ultrasound-guided TAP block (injecting numbing medicine into the abdominal wall) versus injecting the same medicine directly into the surgical wound. Both methods are already used, but it is unclear which provides better pain relief and reduces the need for stronger opioid painkillers. The study includes 300 women aged 18–40 with a normal BMI, and will measure pain scores and opioid use over 24 hours after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bupivacaine
What this could lead to
If one method proves better, it could become the standard for managing pain after cesarean sections, reducing opioid use and improving recovery.
What could go wrong
This is a single-center trial with 300 participants, so results may not apply to all hospitals or patients. Both methods are already used, so the difference may be small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

300 people

The number who actually took part.

Started

Jan 2021

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study subjects will randomly assigned to 3 equal groups (TAP group and infiltration group and Narcotics only group) of patients undergoing elective cesarean section under general anathesia in Ain Shams Maternity hospital

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Patients undergoing elective cesarean section under general anathesia * Pfannenstiel Skin Incision * Age between 18 and 40 years old * BMI between 18 and 35 kg/m2 Exclusion Criteria: * • Patient refusal. * BMI\<18 kg/m2 or\>35 (require different dose of analgesia) * Height \<150 or \> 180 cm (require different dose of analgesia) * Patients with any neurological deficit due to neuropathy and pain score affection * Patients with bleeding disorders which may lead to hematoma * HTN (Vasculopathy which can lead to hematoma). * Cardiac disease ( Vasculopathy on anticoagulant which can lead to hematoma) * DM (decrease systemic and local immunity which can lead to abscess at injection site and due to neuropathy and pain score affection). * Liver disease (defective clotting factors). * A history of relevant drug allergy or Hypersensitivity to any of the drugs used in the study due to impair of proper follow up of pain postoperative * History of recent opioid exposure due to affection on pain score * Local skin infection due to abscess formation * Obstetric complications e.g placenta previa and rupture uterus due to extensive tissue damage and dissection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postoperative pain control are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ain Shams University Maternity Hospital

    Cairo, 11865, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.